Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by canadafanon Nov 24, 2020 12:22pm

314 Views

Post# 31961333

RE:RE:RE:RE:pssssst

Go to the ONC web site & listen to Q3 investor update.
Also read-up on the "investor presentation"

Bottom line
ONColytics biotech is now & has been for years working hard to get its product "Pelareorep" to market to fight cancer.
The term "efficacy", essentially means it has an effect, compared to not having the dosage.
The recent announcment re-Glioblastoma ( brain cancer) showed promising results and efficacy.
That is an early stage study, but on-top-of the breast cancer and multiple melanoma they are working on.
IN only one of the avenues comes to frutition, the company will be worth billions.

Bullboard Posts

Canadian artificial intelligence ETFs